A trial looking at trastuzumab and pertuzumab for HER2 positive breast cancer - APHINITY

This trial is looking at adding a new drug called pertuzumab to trastuzumab (Herceptin) for people who have had surgery for breast cancer.

It is for people whose breast cancer is HER2 positive. This means the breast cancer cells have tested positive for a protein called HER2.

Doctors often treat HER2 positive breast cancer with surgery followed by chemotherapy then trastuzumab. Trastuzumab is a type of biological therapy called a monoclonal antibody. It works by targeting and blocking the HER2 protein on the cancer cell.

Pertuzumab is a monoclonal antibody that works with trastuzumab in targeting the HER2 protein. Information from research so far suggests that giving both these drugs together for HER2 positive breast cancer may be better than just giving one.

The aim of this trial is to find out if giving pertuzumab with trastuzumab is better than trastuzumab alone for people who have had surgery for HER2 positive breast cancer. And to find out more about the side effects of this combination of treatments.